Acurx Pharmaceuticals (ACXP) Projected to Post Quarterly Earnings on Tuesday

Acurx Pharmaceuticals (NASDAQ:ACXP) will likely be announcing its earnings results before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Acurx Pharmaceuticals Stock Performance

Acurx Pharmaceuticals stock opened at $0.45 on Tuesday. Acurx Pharmaceuticals has a 1 year low of $0.44 and a 1 year high of $3.33. The firm has a 50 day moving average price of $0.76 and a 200 day moving average price of $1.34. The company has a market cap of $8.77 million, a price-to-earnings ratio of -0.41 and a beta of -1.71.

Insiders Place Their Bets

In other Acurx Pharmaceuticals news, CEO David P. Luci acquired 49,261 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was bought at an average cost of $1.01 per share, for a total transaction of $49,753.61. Following the completion of the purchase, the chief executive officer now directly owns 1,097,458 shares in the company, valued at $1,108,432.58. This represents a 4.70 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 29.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Acurx Pharmaceuticals in a report on Friday, January 10th.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.